1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Market Access Impact: Asthma/COPD (EU5)

Market Access Impact: Asthma/COPD (EU5)

  • October 2015
  • -
  • Firstword Pharma




Are prescribing constraints costing your brand market share?


Doctors can’t always prescribe the asthma/COPD drugs they want to prescribe. The reason: market barriers—things like pricing, reimbursement, guidelines, patient preferences, and more.


Barriers like these are a threat to leading brands’ market share. But they also offer opportunities for brands to take market share from competitors.


FirstView’s Market Access Impact in Asthma/COPD report takes an in-depth look at the way barriers affect asthma/COPD prescribing, and reveals which brands are winning and losing market share because of it. See what brands are included in this report


Not your market? Click here to see the US Edition







Answering key questions

Packed with physician insight into seven of the leading asthma/COPD brands, Market Access Impact in Asthma/COPD answers key questions like:

Seretide: a top brand in the US, where does Seretide rank in the EU5 market?
Eklira: would eliminating market barriers move Eklira ahead of competing brands?
Foradil: is reimbursement or patient preference the key to Foradil’s market share gains?
Onbrez: which is the bigger problem for Onbrez: guidelines, or formulary availability?
Serevent: which competing brands does Serevent take the most market share from?
Spiriva: with nearly equal barrier-related gains and losses, what can Spiriva do to tip the scales in its favour?
Symbicort: where does over half of Symbicort’s lost share go? (the answer may surprise you)



Key Issues Explored

Market Access Impact in Asthma/COPD explores key issues affecting asthma/COPD drug makers. You’ll learn:

How barriers affect market access:

What brands do doctors prescribe the most?
How many prescriptions do barriers affect?
Which barriers have the biggest effect?

How barriers affect your brand:

How many doctors prescribe your brand? How many don’t, but would consider it?
Why don’t doctors prescribe your brand? What do they prescribe instead?
Which competing brands does your brand take market share from?


A Report Based on Expert Knowledge

Market Access Impact in Asthma/COPD is based on a survey of 150 EU5 physicians—78 pulmonologists and 72 general practitioners.

All respondents have:

Been practicing for 2+ years
Prescribed at least one of the listed products
Seen at least 50 patients with asthma or COPD in total in the last month

Get Answers On The Following Brands

Seretide (fluticasone/salmeterol; GlaxoSmithKline)
Eklira (aclidinium; AstraZeneca)
Foradil (formoterol Novartis/Merck & Co.)
Onbrez (indacaterol; Novartis)
Serevent (salmeterol; GlaxoSmithKline)
Spiriva (tiotropium; Boehringer Ingelheim)
Symbicort (budesonide/formoterol; AstraZeneca)

Add the US report to your order and get a free comparison report
Also available, the Market Access Impact in Asthma/COPD—US edition.

Based on a survey of 100 physicians from the United States, the report reveals how market barriers affect the leading asthma/COPD brands in the US market.

Order the EU5 and US reports together and you’ll receive a free companion report comparing results from both markets.

Email us for details or call +1 212-220-0880 or +44(0)20.7665.9240

MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.


About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Learn more at www.firstwordgroup.com.




Table Of Contents

Market Access Impact: Asthma/COPD (EU5)
1.What are market barriers?
2.About this report
3.About the survey
4.Brands included in the survey
5.Executive summary

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


Download Unlimited Documents from Trusted Public Sources

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Therapy Market in Denmark - Forecast

  • December 2016
    12 pages
  • Therapy  

  • Denmark  

View report >

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.